Sight Sciences, Inc. (NASDAQ:SGHT) CTO Sells $15,075.94 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 5,423 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $2.78, for a total value of $15,075.94. Following the completion of the sale, the chief technology officer now directly owns 1,744,118 shares in the company, valued at approximately $4,848,648.04. The trade was a 0.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

David Badawi also recently made the following trade(s):

• On Wednesday, January 8th, David Badawi sold 3,829 shares of Sight Sciences stock. The shares were sold at an average price of $3.26, for a total value of $12,482.54.
• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The stock was sold at an average price of $3.52, for a total transaction of $10,950.72.

Sight Sciences Stock Down 1.0 %

SGHT stock opened at $2.93 on Friday. Sight Sciences, Inc. has a 1 year low of $2.67 and a 1 year high of $8.45. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. The business has a 50 day simple moving average of $3.53 and a 200-day simple moving average of $5.29.

Sight Sciences (NASDAQ:SGHT) last issued its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The company had revenue of $20.16 million during the quarter, compared to analysts’ expectations of $20.41 million. Sell-side analysts anticipate that Sight Sciences, Inc. will post -1.01 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Lake Street Capital decreased their price objective on shares of Sight Sciences from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Wednesday, January 15th. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a report on Tuesday, January 14th. Morgan Stanley reduced their target price on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, November 11th. Citigroup lowered their price target on Sight Sciences from $5.80 to $4.60 and set a “neutral” rating on the stock in a research note on Wednesday, December 11th. Finally, Piper Sandler reissued a “neutral” rating and issued a $5.50 price objective (down from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, Sight Sciences presently has a consensus rating of “Hold” and an average price target of $4.72.

Hedge Funds Weigh In On Sight Sciences

A number of institutional investors have recently bought and sold shares of SGHT. KCK LTD. acquired a new stake in shares of Sight Sciences during the 4th quarter worth approximately $15,925,000. Long Focus Capital Management LLC increased its stake in Sight Sciences by 86.9% during the second quarter. Long Focus Capital Management LLC now owns 560,594 shares of the company’s stock worth $3,739,000 after acquiring an additional 260,594 shares during the last quarter. B. Riley Wealth Advisors Inc. purchased a new stake in Sight Sciences in the second quarter valued at $1,234,000. Millrace Asset Group Inc. acquired a new position in shares of Sight Sciences in the 3rd quarter valued at $874,000. Finally, State Street Corp grew its holdings in shares of Sight Sciences by 17.4% during the 3rd quarter. State Street Corp now owns 646,776 shares of the company’s stock worth $4,075,000 after purchasing an additional 95,843 shares during the period. 55.51% of the stock is owned by hedge funds and other institutional investors.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.